These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 9862830

  • 1. Glucagon-like peptide-1: a potent regulator of food intake in humans.
    Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C.
    Gut; 1999 Jan; 44(1):81-6. PubMed ID: 9862830
    [Abstract] [Full Text] [Related]

  • 2. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
    Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM.
    Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
    [Abstract] [Full Text] [Related]

  • 3. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.
    Long SJ, Sutton JA, Amaee WB, Giouvanoudi A, Spyrou NM, Rogers PJ, Morgan LM.
    Br J Nutr; 1999 Apr; 81(4):273-9. PubMed ID: 10999014
    [Abstract] [Full Text] [Related]

  • 4. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.
    Chelikani PK, Haver AC, Reidelberger RD.
    Am J Physiol Regul Integr Comp Physiol; 2005 Jun; 288(6):R1695-706. PubMed ID: 15718384
    [Abstract] [Full Text] [Related]

  • 5. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S, Hellström PM.
    Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
    [Abstract] [Full Text] [Related]

  • 6. A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.
    Drewes C, Nauck MA, Horn R, Holst J, Schmiegel W, Brabant G.
    Acta Diabetol; 1997 Oct; 34(3):230-4. PubMed ID: 9401646
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
    Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C.
    Am J Physiol; 1999 May; 276(5):R1541-4. PubMed ID: 10233049
    [Abstract] [Full Text] [Related]

  • 8. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men.
    Gutzwiller JP, Degen L, Matzinger D, Prestin S, Beglinger C.
    Am J Physiol Regul Integr Comp Physiol; 2004 Sep; 287(3):R562-7. PubMed ID: 15105167
    [Abstract] [Full Text] [Related]

  • 9. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
    Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR.
    Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men.
    Brennan IM, Feltrin KL, Horowitz M, Smout AJ, Meyer JH, Wishart J, Feinle-Bisset C.
    Am J Physiol Regul Integr Comp Physiol; 2005 Jun; 288(6):R1477-85. PubMed ID: 15695321
    [Abstract] [Full Text] [Related]

  • 11. Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans.
    Melhorn SJ, Tyagi V, Smeraglio A, Roth CL, Schur EA.
    Appetite; 2014 Nov; 82():85-90. PubMed ID: 25049134
    [Abstract] [Full Text] [Related]

  • 12. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.
    Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A.
    Int J Obes Relat Metab Disord; 2001 Jun; 25(6):781-92. PubMed ID: 11439290
    [Abstract] [Full Text] [Related]

  • 13. Effect of peptide YY3-36 on food intake in humans.
    Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C.
    Gastroenterology; 2005 Nov; 129(5):1430-6. PubMed ID: 16285944
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
    Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M.
    Diabetes; 2001 Nov; 50(11):2530-9. PubMed ID: 11679431
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.